Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Share-based Compensation (2016 - 2025)

Haemonetics has reported Share-based Compensation over the past 17 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $7.8 million for Q4 2025, down 5.05% from a year ago — trailing twelve months through Dec 2025 was $31.6 million (up 5.04% YoY), and the annual figure for FY2025 was $29.6 million, up 4.6%.
  • Share-based Compensation for Q4 2025 was $7.8 million at Haemonetics, up from $7.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for HAE hit a ceiling of $9.3 million in Q2 2025 and a floor of $5.1 million in Q2 2022.
  • Median Share-based Compensation over the past 5 years was $7.0 million (2023), compared with a mean of $7.0 million.
  • Biggest five-year swings in Share-based Compensation: fell 28.31% in 2022 and later skyrocketed 38.47% in 2023.
  • Haemonetics' Share-based Compensation stood at $6.0 million in 2021, then increased by 25.29% to $7.5 million in 2022, then decreased by 3.66% to $7.2 million in 2023, then grew by 13.81% to $8.2 million in 2024, then dropped by 5.05% to $7.8 million in 2025.
  • The last three reported values for Share-based Compensation were $7.8 million (Q4 2025), $7.6 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.